Development of a Cascade-Targeting Oral Vaccine via Glycoprotein 2 on Intestinal Microfold Cells for Cancer Immunotherapy
Source abstract
Abstract
Oral cancer vaccines are convenient and safe, with the presence of gut-associated lymphoid tissue (GALT) involved intestinal Peyer’s patch (PPs) containing microfold (M) cells and housing abundant underneath dendritic cells (DCs). Here, we found that the endocytic receptors glycoprotein 2 (GP2) and dectin-1 are respectively expressed on M cells and DCs with high specificity. Then, we discovered a gastrointestinal hydrolysis-resistant D-peptide D GPBP-2(1-8) targeting GP2 by phage display screening and optimization. D GPBP-2(1-8) was conjugated to β-glucan (dectin-1 ligand)-containing yeast capsules (GP2-YCs) to design a cascade-targeting oral vaccine platform, which can help the antigen to efficiently cross intestinal M cells and subsequently be endocytosed by underneath DCs, thus activating CD8 + T cells. More importantly, this oral vaccine can evoke not only cellular but also humoral and mucosal immune responses. Therefore, this cascade-targeting oral vaccine could serve as a novel platform for cancer immunotherapy and infectious disease prevention as well.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Transgenic Plants and Applications · Immune Cell Function and Interaction
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmaceutical Sciences (Shenzhen)
Shenzhen Campus of Sun Yat-sen University
Funding
Shenzhen Medical Research Fund · The Guangdong Basic and Applied Basic Research Foundation · The Fundamental Research Funds for the Central Universities, Sun Yat-sen University · The Postdoctoral Fellowship Program of CPSF · The National Natural Science Foundation of China · The "Pearl River Talent Plan" Innovation and Entrepreneurship Team Project of Guangdong Province
References (36)
Show source-provided references
1. 10.1016/j.jconrel.2024.07.05610.1016/j.jconrel.2024.07.056 ↗
2. 10.1038/s41577-021-00583-210.1038/s41577-021-00583-2 ↗
3. 10.1016/j.biomaterials.2023.12231210.1016/j.biomaterials.2023.122312 ↗
4. 10.1016/j.addr.2011.07.00310.1016/j.addr.2011.07.003 ↗
5. 10.1038/s41596-020-00482-110.1038/s41596-020-00482-1 ↗
6. 10.1038/s41467-019-13883-y10.1038/s41467-019-13883-y ↗
7. 10.1038/s41551-022-00886-210.1038/s41551-022-00886-2 ↗
8. 10.1007/s13770-023-00543-y10.1007/s13770-023-00543-y ↗
9. 10.1007/s00428-003-0898-810.1007/s00428-003-0898-8 ↗
10. 10.1093/jb/mvv12110.1093/jb/mvv121 ↗
11. Sauls R. S. · 2023
12. 10.3390/ijms23221420010.3390/ijms232214200 ↗
13. 10.1053/j.gastro.2011.11.03910.1053/j.gastro.2011.11.039 ↗
14. 10.1016/0016-5085(93)91004-210.1016/0016-5085(93)91004-2 ↗
15. 10.1016/j.apsb.2022.08.01010.1016/j.apsb.2022.08.010 ↗
16. 10.1002/adma.20210413910.1002/adma.202104139 ↗
17. 10.1016/j.biomaterials.2018.10.04110.1016/j.biomaterials.2018.10.041 ↗
18. 10.1016/j.carbpol.2023.12132910.1016/j.carbpol.2023.121329 ↗
19. 10.1126/sciadv.adh782010.1126/sciadv.adh7820 ↗
20. 10.1016/j.carbpol.2023.12116310.1016/j.carbpol.2023.121163 ↗
21. 10.1186/1756-8722-2-2510.1186/1756-8722-2-25 ↗
22. 10.1007/s10753-016-0404-510.1007/s10753-016-0404-5 ↗
23. 10.1038/s41467-021-27750-210.1038/s41467-021-27750-2 ↗
24. 10.1002/advs.20220149610.1002/advs.202201496 ↗
25. 10.1186/s12951-023-01832-310.1186/s12951-023-01832-3 ↗
26. 10.1021/acs.molpharmaceut.8b0035710.1021/acs.molpharmaceut.8b00357 ↗
27. 10.1021/acsabm.9b0037910.1021/acsabm.9b00379 ↗
28. 10.1002/adma.20210070110.1002/adma.202100701 ↗
29. 10.1038/s41467-020-20348-010.1038/s41467-020-20348-0 ↗
30. 10.1371/journal.pbio.100165810.1371/journal.pbio.1001658 ↗
31. 10.1038/s41586-021-03852-110.1038/s41586-021-03852-1 ↗
32. 10.1038/nature0852910.1038/nature08529 ↗
33. 10.4049/jimmunol.160006310.4049/jimmunol.1600063 ↗
34. 10.1177/247255521769048310.1177/2472555217690483 ↗
35. 10.3390/pharmaceutics1301001810.3390/pharmaceutics13010018 ↗
36. 10.3390/ijms2216867710.3390/ijms22168677 ↗